CD8A and neoplasm: To this end, we focused on two tumor-reactive CD8+ T cell clones; gp100 melanoma antigen-specific Pmel-1 (22) and B16F10 Reactive Clone 1 (B16RC1), which was originally cloned from CD137high CD8+ TILs in B16F10 tumor model (23).